CD274 and metastatic melanoma: Ye et al. [5] combined Golgi apparatus-PD-L1 (programmed death-ligand 1)-/-exosome hybrid membrane coated nanoparticles (GENPs) and anti-PD-L1 immunotherapy through the sprayable in situ hydrogel, prolonging survival periods in mice models with incomplete metastatic melanoma resection.